Literature DB >> 6422575

The value of screening for glaucoma with tonometry.

D M Eddy, L E Sanders, J F Eddy.   

Abstract

This paper estimates the value of performing Schiotz tonometry to detect glaucoma in an asymptomatic patient. About 9% of adults over 40 will be found on a single Schiotz tonometry test to have elevated intraocular pressure (IOP). On work-up, about 1 out of 50 of these individuals with high IOP will be found to have glaucoma. Tonometry, however, will miss about half of all patients with glaucoma because they do not have elevated IOPs at the time of the test. Pilocarpine or epinephrine are the most commonly used drugs to treat the disease, but they are not always effective in lowering a patient's IOP or in stopping the progression of field defects. From the available evidence it does not appear that earlier diagnosis makes a substantial difference in the patient's outcome. If all individuals over 40 years of age in a city of 1,000,000 were screened, the total cost of finding and treating about 484 people with chronic simple glaucoma would be on the order of $4,944,866 or about $13,000 per patient potentially benefited. Screening with tonometry does not appear to be warranted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6422575     DOI: 10.1016/0039-6257(83)90097-8

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  14 in total

1.  Treatment of raised intraocular pressure and prevention of glaucoma.

Authors:  R Wormald
Journal:  BMJ       Date:  2003-04-05

2.  Screening for glaucoma in general practice.

Authors:  A Aggarwal
Journal:  Br J Gen Pract       Date:  1991-05       Impact factor: 5.386

3.  Population and high-risk group screening for glaucoma: the Los Angeles Latino Eye Study.

Authors:  Brian A Francis; Rohit Varma; Cheryl Vigen; Mei-Ying Lai; Jonathan Winarko; Betsy Nguyen; Stanley Azen
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-05       Impact factor: 4.799

4.  Changing concepts of primary open-angle glaucoma and early detection.

Authors:  R N Battista; P Huston; M W Davis
Journal:  Can Fam Physician       Date:  1986-07       Impact factor: 3.275

Review 5.  Screening for glaucoma. Why is the disease underdetected?

Authors:  M W Tuck; R P Crick
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

6.  Levobunolol compared with timolol: a four-year study.

Authors:  O Geyer; M Lazar; G D Novack; D Shen; C Y Eto
Journal:  Br J Ophthalmol       Date:  1988-12       Impact factor: 4.638

Review 7.  The economic implications of glaucoma: a literature review.

Authors:  Jordana K Schmier; Michael T Halpern; Mechelle L Jones
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial.

Authors:  M A Kass
Journal:  Trans Am Ophthalmol Soc       Date:  1989

9.  Clinical evaluation of a multi-fixation campimeter for the detection of glaucomatous visual field loss.

Authors:  E Mutlukan; B E Damato; J L Jay
Journal:  Br J Ophthalmol       Date:  1993-06       Impact factor: 4.638

10.  Design of low cost glaucoma screening.

Authors:  A G Niessen; C T Langerhorst; H C Geijssen; E L Greve
Journal:  Doc Ophthalmol       Date:  1997       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.